Clinical trials: Ticagrelor
Thrombosis, Bleeding
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
The goal of this retrospective clinical trial is to find out association antiplatelet and anticoagulant therapy with perioperative complications in non-cardiac vascular surgery in patients .
- Conditions
- Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure
- Trial name
- NCT07358416
- Testing
- Aspirin, Clopidogrel, Ticagrelor
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- Petrovsky National Research Centre of Surgery
Angina, Stable, Acute Coronary Syndrome
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)
The aim of this study is to assess the efficacy and safety of the CYP2C19 genotype guided antiplatelet treatment strategy, using clopidogrel in non-carriers of a CYP2C19*2 or *3 allele and ticagrelor in carriers of a CYP2C19*2 or…
- Conditions
- Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents, Genotype
- Trial name
- NCT03783351
- Testing
- CYP2C19 genotype testing
- Where
- 9 sites in China
- Volunteers
- 4,009 people
- Sponsor
- Beijing Anzhen Hospital
Chronic Coronary Disease
One-Month DAPT in CABG Patients
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
- Trial name
- ODIN (NCT05997693)
- Testing
- Ticagrelor 90 MG, Low-dose aspirin
- Where
- 22 sites in United States, Austria and 4 more
- Volunteers
- 700 people
- Sponsor
- Weill Medical College of Cornell University
Antiphospholipid Syndrome, Arterial Thrombosis
Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS
The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12…
- Trial name
- NCT05646394
- Testing
- Dual antiplatelet therapy, Combined antithrombotic therapy, Vitamin K antagonist standard intensity
- Where
- 3 sites in Argentina, Canada
- Volunteers
- 150 people
- Sponsor
- McMaster University
Intracranial Atherosclerosis
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
Stroke is an important cause of death, disability, and memory problems in adults. The build-up of plaque in arteries inside the brain is known as "intracranial atherosclerotic disease" or "ICAD" for short, and can reduce blood…
- Trial name
- NUANCE-ICAD (NCT06714526)
- Testing
- Point-of-Care CYP2C19 Testing, ticagrelor + aspirin, clopidogrel + aspirin
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Sunnybrook Health Sciences Centre
Coronary Artery Disease
DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injury
Heart attacks are most commonly caused by rupture of fatty deposits (plaques) within the wall of heart blood vessels. It appears that this process can also frequently occur without causing any symptoms and these events likely…
- Trial name
- DIAMOND (NCT02110303)
- Testing
- Ticagrelor
- Where
- United Kingdom
- Volunteers
- 220 people
- Sponsor
- University of Edinburgh
Acute Myocardial Infarction
Ticagrelor De-escalation Strategy in AMI Patients
DAPT de-escalation strategies to reduce bleeding include de-escalation of DAPT intensity (downgrading from potent P2Y12 inhibitor at conventional doses to either clopidogrel or reduced-dose prasugrel) or abbreviation of DAPT…
- Trial name
- NCT04755387
- Testing
- De-escalation strategy, Conventional strategy
- Where
- South Korea
- Volunteers
- 2,312 people
- Sponsor
- Dong-A University
Ischemic Stroke
Combining Aspirin With Ticagrelor or Cilostazol in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 200mg cilostazol were assessed…
- Trial name
- NCT06591377
- Testing
- Ticagrelor 90 MG, Cilostazol 100 MG, Aspirin 75mg
- Where
- 2 sites in Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Acute Coronary Syndrome
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin
Heart attacks are usually caused by clots in a coronary artery, depriving the heart muscle of blood. Platelets are the main type of blood cell causing clots to form and physicians typically give a combination of two anti-platelet…
- Trial name
- WILLOW TREE (NCT03869268)
- Testing
- Aspirin, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Stroke, Stroke, Ischemic
Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis
REDUCING INFLAMMATION IN ISCHEMIC STROKE WITH COLCHICINE, AND TICAGRELOR IN HIGH-RISK PATIENTS-EXTENDED TREATMENT IN ISCHEMIC STROKE.
- Conditions
- Stroke, Stroke, Ischemic, Atherosclerosis, Myocardial Infarction
- Trial name
- RIISC-THETIS (NCT05476991)
- Testing
- Colchicine 0.5 MG, Ticagrelor 90mg, Aspirin 75-300mg
- Where
- France
- Volunteers
- 2,800 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemic Stroke
Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA
Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed…
- Trial name
- NCT06591338
- Testing
- Ticagrelor 90 MG, Clopidogrel, Aspirin 75 Mg Oral Tablet
- Where
- Egypt
- Volunteers
- 900 people
- Sponsor
- Kafrelsheikh University
Acute Coronary Syndrome
Ticagrelor and ASA vs. ASA Only After Isolated Coronary Artery Bypass Grafting in Patients With Acute Coronary Syndrome
The study is a Randomised Registry-based Clinical Trial (RRCT) to assess whether dual antiplatelet therapy with ticagrelor and ASA compared to ASA alone improves outcome after isolated CABG in patients with acute coronary…
- Trial name
- TACSI (NCT03560310)
- Testing
- Ticagrelor 90mg twice daily and ASA 75-100 mg daily, ASA 75-160 mg daily
- Where
- 22 sites in Denmark, Finland and 3 more
- Volunteers
- 2,201 people
- Sponsor
- Vastra Gotaland Region
Coronary Artery Disease
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI
Clopidogrel is the P2Y12 inhibitor of choice in PCI patients requiring OAC. However, concerns have been raised based on the notion that a considerable number of patients may have inadequate response to clopidogrel.
- Trial name
- SWAP-AC-2 (NCT04483583)
- Testing
- Ticagrelor 60mg, Clopidogrel
- Where
- United States
- Volunteers
- 81 people
- Sponsor
- University of Florida
Stent Thrombosis, Myocardial Infarction, Acute
TADCLOT- a Double Blind Randomized Controlled Trial
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
- Trial name
- TADCLOT (NCT06318481)
- Testing
- Ticagrelor 90 MG, Clopidogrel
- Where
- Pakistan
- Volunteers
- 2,200 people
- Sponsor
- National Institute of Cardiovascular Diseases, Pakistan
Healthy
A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects
The primary objective of this study is to assess the pharmacodynamic (PD) effects of clopidogrel, prasugrel, and ticagrelor when administered after a single subcutaneous (s.c.) dose of ACT-246475 in healthy male and female…
- Trial name
- NCT03430661
- Testing
- ACT-246475, Clopidogrel, Prasugrel
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Viatris Innovation GmbH
Acute Coronary Syndrome
TicagRelor Or Clopidogrel in Severe and Terminal Chronic Kidney Disease Patients Undergoing PERcutaneous Coronary Intervention for an Acute Coronary Syndrome.
Ticagrelor is a potent and fast-acting P2Y12-ADP receptor antagonist recommended as first-line agent in ACS (2). This drug was associated with a 20% relative reduction in the rate of MACE in ACS patients undergoing PCI compared…
- Trial name
- TROUPER (NCT03357874)
- Testing
- Clopidogrel, Ticagrelor
- Where
- France
- Volunteers
- 259 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Coronary Artery Disease
Ticagrelore Alone Post PCI
After PCI for CCS patients, single center double blind randomization will be done and patients will receive aspirin 80 mg and clopidogrel 75 mg versus 90 mg two times daily of ticagrelor, for 6 months and MACE will be followed in…
- Trial name
- TICALONE (NCT06509893)
- Testing
- aspirin 80 mg and clopidogrel 75 mg daily, Ticagrelor 90 MG
- Where
- 2 sites in Iran
- Volunteers
- 5,400 people
- Sponsor
- Shiraz University of Medical Sciences
Ischemic Stroke, Patent Foramen Ovale
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
A registry of patients from the Asia-Pacific region with PFO and ischemic stroke, designed to study the characteristics, investigations, treatment and outcomes using real-world data.
- Trial name
- PACIFIC-PFO (NCT06983795)
- Testing
- PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management
- Where
- Singapore
- Volunteers
- 1,000 people
- Sponsor
- National University Hospital, Singapore
Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR)
The Effect of IV Cangrelor and Oral Ticagrelor Study
Major heart attacks are caused by a number of factors, the two major of which are furring up of a coronary artery with atheroma and then sudden clot formation on this area leading to a blockage and interruption of blood flow.
- Conditions
- Acute Coronary Syndrome (ACS), High On-treatment Platelet Reactivity (HTPR), Microvascular Obstruction (MVO), ST-segment Elevation Myocardial Infarction (STEMI)
- Trial name
- NCT02733341
- Testing
- Cangrelor, Ticagrelor
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
Ischemic Stroke, Transient Ischemic Attack
Ticagrelor Based De-Escalation of Dual Antiplatelet Therapy in Ischemic Stroke
This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy…
- Trial name
- DEDAPT-TICA (NCT06653348)
- Testing
- Ticagrelor 60 + Aspirin, Ticagrelor 90 + aspirin
- Where
- Iran
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Mazandaran University of Medical Sciences